Related Experiment Videos
[Expression of p-glycoprotein in malignant solid human tumors]
Piotr G Grelewski1, Julia K Bar
1Katedry i Zakładu immunologii Klinicznej AM we Wrocławiu.
Ginekologia Polska
|May 11, 2002
Abstract:
One of the main causes of cancer resistance to chemotherapy is multidrug resistance. The role of P-glyco-protein in different solid human cancers was assessed by taking into account clinico-pathological parameters. The application of inhibitors when multidrug resistance appeared was discussed. The participation of other proteins and enzymes in adding resistance to the cancer cells was stressed.
Insights
Multidrug resistance (MDR) is a key cause of chemotherapy failure in solid human cancers. This study assesses P-glycoprotein
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) significantly limits chemotherapy efficacy in solid human cancers.
- P-glycoprotein (P-gp) is a major transporter implicated in MDR.
- Understanding MDR mechanisms is crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To evaluate the role of P-glycoprotein in various solid human cancers.
- To correlate P-gp expression with clinico-pathological parameters.
- To discuss therapeutic strategies involving P-gp inhibitors for overcoming MDR.
Main Methods:
- Assessment of P-glycoprotein expression in solid human cancer tissues.
- Correlation analysis with clinico-pathological data.
- Literature review on P-gp inhibitors and other resistance mechanisms.
Main Results:
- P-glycoprotein expression varies across different solid human cancers.
- Clinico-pathological parameters may influence P-gp levels.
- Other proteins and enzymes also contribute to cancer cell resistance.
Conclusions:
- P-glycoprotein plays a significant role in MDR across solid human cancers.
- Targeting P-gp with inhibitors is a potential strategy to combat chemotherapy resistance.
- A multifactorial approach considering various resistance mechanisms is necessary for effective cancer therapy.